3690 |
INTEGRIN SUBUNIT BETA 3 |
ITGB3 |
BDPLT16 |
BDPLT2 |
CD61 |
GP3A |
GPIIIa |
GT |
173470 |
6156 |
ENSG00000259207 |
ENSG00000259753 |
OTTHUMG00000171956 |
OTTHUMG00000171957 |
ITB3_HUMAN |
P05106 |
CD_antigen=CD61 |
Platelet membrane glycoprotein IIIa |
Integrin beta-3 |
PA205 |
ENSG00000056345 |
INTEGRIN BETA-3 PRECURSOR (PLATELET MEMBRANE GLYCOPROTEIN IIIA) (GPIIIA) (CD61 ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:P05106] |
AC068234.1 |
BDPLT24 |
GT2 |
Target Subclass | Integrin |
Target Main Class | Receptors |
Target Subclass | Other_receptors |
Transmembrane Helix Count | 1 |
Human Readable Name | DRUGGABLE GENOME |
Uniprot Evidence | 1: Evidence at protein level |
Interpro Type | Domain |
Uniprot Status | Swiss-Prot |
Interpro Acc | IPR002369 |
Interpro Short Name | Integrin_bsu_N |
Interpro Name | Integrin beta subunit, N-terminal |
Target Class | Receptors |
Target Subclass | Receptors |
Gene Biotype | PROTEIN_CODING |
CELL SURFACE |
DRUGGABLE GENOME |
inhibitor (inhibitory) |
Trial Name | eptifibatide,Integrilin |
Novel drug target | Established target |
Mechanism of Interaction | Integrin alpha-IIb/beta-3 inhibitor |
antibody (inhibitory) |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Integrin alpha-IIb/beta-3 inhibitor |
Direct Interaction | yes |
Trial Name | abciximab, c7E3,ReoPro |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Trial Name | cilengitide. EMD-121974 |
Novel drug target | Established target |
Mechanism of Interaction | Integrin alpha-V/beta-3 antagonist |
inhibitor (inhibitory) |
Mechanism of Interaction | Integrin alpha-IIb/beta-3 inhibitor |
Direct Interaction | yes |
antagonist (inhibitory) |
Mechanism of Interaction | Integrin alpha-IIb/beta-3 antagonist |
Direct Interaction | yes |
n/a |
Novel drug target | Established target |
Trial Name | YM-028, gantofiban |
antagonist (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Integrin alpha-V/beta-3 antagonist |
Trial Name | CNTO-95 |
antibody (inhibitory) |
antagonist (inhibitory) |
Mechanism of Interaction | Integrin alpha-V/beta-3 antagonist |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Integrin alpha-V/beta-3 inhibitor |
Direct Interaction | yes |
n/a |
Trial Name | GLPG0187 |
Novel drug target | Established target |
AC068234.1 | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
ITGB3 | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
ITGB3 | Gene Symbol |
Target Subclass | Integrin |
Target Class | Receptors |
Target Subclass | Receptors |
ITGB3 | Gene Symbol |
ITB3_HUMAN | Uniprot Id |
3690 | Entrez Gene Id |
Target Subclass | Integrin |
Target Main Class | Receptors |
Target Subclass | Other_receptors |
3690 | Entrez Gene Id |
INTEGRIN BETA-3 | Uniprot Protein Name |
ENSG00000259207 | Ensembl Gene Id |
Human Readable Name | DRUGGABLE GENOME |
Uniprot Evidence | 1: Evidence at protein level |
Interpro Type | Domain |
DRUGGABLE GENOME |
INTEGRIN BETA-3 PRECURSOR (PLATELET MEMBRANE GLYCOPROTEIN IIIA) (GPIIIA) (CD61 ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:P05106] | Description |
ITGB3 | Display Id |
ENSG00000056345 | Ensembl Gene Id |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
PA205 | PharmGKB ID |
ENSG00000259207 | Gene Symbol |
ITGB3 | Ensembl Id |
DRUGGABLE GENOME |
ITGB3 | Gene Symbol |
GP3A | GENE_SYMBOL |
ITGB3 | GENE_SYMBOL |
Integrin beta-3 | UNIPROT |
ENSG00000259753 | Gene Symbol |
Ensembl Id |
DRUGGABLE GENOME |
GP3A | GO Gene Synonym |
CELL SURFACE |